Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers

NCT ID NCT05665062

Ongoing Disease control Sponsor: Synthekine Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), along with a supporting drug (STK-009) designed to help those cells survive and work better. The main goal is to check the safety and find the best dose, while also looking at whether the cancer shrinks or disappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SYNCAR-001 (a type of CAR T-cell therapy) and STK-009 (a supporting drug)
What this could lead to
If it works, this could offer a new treatment option for people with certain blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 36 participants, so it is primarily testing safety. The therapy may not work, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLL/SLL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma indolent B-cell non-Hodgkin lymphoma large B-cell lymphoma mantle cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL/SLL DIFFUSE LARGE B CELL LYMPHOMA FOLLICULAR LYMPHOMA INDOLENT B-CELL NON-HODGKIN LYMPHOMA LARGE B-CELL LYMPHOMA MANTLE CELL LYMPHOMA NHL

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Roswell Park

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.